Dogwood Therapeutics has strengthened its financial position by converting $19.5 million in debt to equity, removing all existing debt from its balance sheet and improving its investment profile.
Dogwood Therapeutics (DWTX) has seen its stock surge 368% year-to-date, driven by the upcoming Phase 2b trial of Halneuron®, a non-opioid treatment for chemotherapy-induced neuropathic pain. The company's innovative Nav 1.7 sodium channel inhibitor represents a potential breakthrough in addressing chronic pain without addiction risks, targeting a $1.5 billion market opportunity.
Dogwood Therapeutics has commenced patient dosing in a Phase 2b trial (HALT-CINP) to evaluate Halneuron® for chemotherapy-induced neuropathic pain (CINP).
Virios Therapeutics and Wex Pharmaceuticals have merged in an all-stock transaction, creating Dogwood Therapeutics (NASDAQ: DWTX), focused on clinical development of Halneuron®, IMC-1, and IMC-2.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.